Navigation Links
Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer
Date:8/22/2014

LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.

When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise T. Chow, Ph.D. and Thomas Broker, Ph.D., who presented the findings at the Seattle conference. The National Institute of Allergy and Infectious Diseases in the National Institutes of Health funded Chow's work at the University of Alabama, Birmingham.

"HTI-1968 is potent and selective, inhibiting the growth of these high-risk HPV types. Dr. Chow's findings, though early stage, offer hope to millions of women infected by one of these high-risk HPV types, including two that are responsible for 70 percent of cervical cancer cases," said Hera Therapeutics CEO Karl Hostetler, M.D.. Currently surgery is the only therapy available to women who have persistent infection with these types of HPV and show signs of abnormal cells.

Hera Therapeutics is developing a topical, non-surgical approach to treat HPV, which could alter the standard of care while preserving structural integrity of the cervix.

Approximately 96 million people worldwide, men and women, are infected with HPV-16 or HPV-18, according to the Centers for Disease Control. Almost 4,000 women in the U.S. die from invasive cervical cancer each year, according to the CDC.

While cervical cancer vaccines prevent infection from the disease, they are not approved by the FDA for marketing to people over 26-years-old and have not demonstrated efficacy in people already infected with the HPV virus.

About Hera Therapeutics Inc.

Using a new medicinal chemistry platform, Hera Therapeutics Inc. is focused on the research, development and commercialization of direct acting antivirals for infections with the human papillomavirus, herpes group viruses, HIV and animal retroviruses.

Hera Therapeutics was founded in 2012 by Karl Hostetler, M.D., a professor emeritus at University of California, San Diego, who was previously a founder of three biotech companies, including Chimerix, Triangle Pharmaceuticals and Vical.


'/>"/>
SOURCE Hera Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
2. Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite
3. Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
4. Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
5. FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
6. TRU-D Tested in Most Comprehensive UV Disinfection Study to Date
7. Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
8. R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
9. Study: 1 out of 5 adult orthopaedic trauma patients sought additional providers for narcotic prescriptions
10. Study Helps Medical Education Leaders Navigate the New Regulatory and Financial Landscape
11. BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... 2017 Sapheneia and Scannerside received FDA 510(k) ... is a third-party Vendor neutral CT product that makes ... compliance with current MITA standards. ... solution is specifically designed to provide CT operators, prior ... doses over a predefined threshold. Scannerside Dose Check is ...
(Date:9/5/2017)...  Getinge, a leading global provider of innovative ... program -- "Color for the Kids!" -- to ... by The Children,s Heart Foundation. Pediatric patients and ... encouraged to download a coloring picture at ... the gallery on the website. For each artwork ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Public outrage over ... pollutants have fallen on deaf ears, leaving the water industry itself to research, develop ... stays ahead of the curve in the field of natural alkaline water ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void ... first in the U.S. to incorporate magnesium, a critical property for bone health ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Ron Norman, CEO ... today the importance of making a distinct rather than generic impression in the job ... to look through a stack of resumes knows that the first impression they give ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... positively linked to the Certified Emergency Nurse (CEN®) certification according to ... (BCEN). The value of certification study, conducted by the Human Resources Research Organization ...
Breaking Medicine News(10 mins):